UX111 resubmission accepted
Ultragenyx’s resubmitted biologics licence application for its MPS IIIA gene therapy, UX111, has been accepted by FDA and assigned a PDUFA date of September 19, 2026. Acceptance signals that gene‑therapy programmes are still progressing through regulatory review even as evidentiary expectations tighten. For manufacturers and CDMOs, these resubmissions underscore the importance of tightly linked CMC records and clear batch‑level evidence packages. (cgtlive.com)
Children with Sanfilippo syndrome type A lose brain function because they cannot make enough sulfamidase, the enzyme that clears heparan sulfate, so waste builds up inside cells the way trash piles up when garbage pickup stops. (pubmed.ncbi.nlm.nih.gov) Ultragenyx is trying to fix that with UX111, a one-time gene therapy that uses adeno-associated virus 9, a disabled delivery virus, to carry a working copy of the SGSH gene into cells. (ultragenyx.com) The treatment is given by intravenous infusion, which means it goes into a vein, and the goal is to help cells start making the missing enzyme so they can break down glycosaminoglycans, the long sugar chains that accumulate in this disease. (ultragenyx.com) Now the regulatory part has moved forward again: on April 2, 2026, Ultragenyx said the Food and Drug Administration accepted its resubmitted biologics license application for UX111 and set a decision date of September 19, 2026. (ultragenyx.com) (cgtlive.com) A biologics license application is the company’s formal request to sell a biologic drug in the United States, and acceptance means the Food and Drug Administration decided the filing was complete enough to start review. (fda.gov) (cgtlive.com) This is a second trip through that process because the first application got a complete response letter in July 2025, which is the Food and Drug Administration’s notice that it will not approve the product in its current form. (sec.gov) (cgtlive.com) Ultragenyx said that 2025 letter focused on chemistry, manufacturing and controls, the records that show how a therapy is made and tested, plus observations from manufacturing facility inspections, rather than on new clinical safety problems. (sec.gov) When a gene therapy hits that kind of delay, the issue is often less like inventing a new engine and more like proving every bolt on every engine was tightened the same way in every factory run. (sec.gov) (cgtlive.com) The resubmitted package added longer-term data on neurologic benefit from the Transpher A study, the ongoing pivotal trial Ultragenyx is using to support accelerated approval. (cgtlive.com) (ultragenyx.com) If UX111 is approved, Ultragenyx says it would be the first approved treatment for Sanfilippo syndrome type A, a rare childhood disease marked by progressive neurodegeneration and early death. (ultragenyx.com)
